Virtu Financial LLC Purchases 56,822 Shares of Novo Nordisk A/S (NYSE:NVO)

Virtu Financial LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 167.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 90,751 shares of the company's stock after purchasing an additional 56,822 shares during the quarter. Virtu Financial LLC's holdings in Novo Nordisk A/S were worth $7,806,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Novo Nordisk A/S in the fourth quarter worth $404,910,000. Sustainable Growth Advisers LP boosted its holdings in shares of Novo Nordisk A/S by 23.6% in the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after buying an additional 1,021,498 shares during the last quarter. Amundi grew its position in shares of Novo Nordisk A/S by 26.4% in the 4th quarter. Amundi now owns 3,311,456 shares of the company's stock valued at $283,615,000 after acquiring an additional 692,567 shares during the period. Parnassus Investments LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $51,072,000. Finally, DAVENPORT & Co LLC increased its holdings in shares of Novo Nordisk A/S by 75.1% in the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company's stock valued at $90,477,000 after purchasing an additional 451,641 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 2.5 %

Shares of NVO traded down $1.86 during mid-day trading on Wednesday, reaching $71.74. The company's stock had a trading volume of 7,578,994 shares, compared to its average volume of 5,456,012. The company's fifty day moving average price is $83.01 and its two-hundred day moving average price is $99.94. Novo Nordisk A/S has a 52 week low of $71.62 and a 52 week high of $148.15. The stock has a market cap of $321.94 billion, a PE ratio of 21.81, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 47.72%.

Analysts Set New Price Targets

A number of analysts have issued reports on NVO shares. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Moderate Buy" and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.